samedan logo
 
 
 
spacer
home > ebr > summer 2004 > driving productivity through strategic partnering
PUBLICATIONS
European Biopharmaceutical Review

Driving Productivity through Strategic Partnering

It has been said: "research takes money and generates ideas, innovation takes ideas and generates money". In reality, a pharmaceutical company must be successful at both if it is to continue to create exciting new medicines offering significant improvements to patients' lives. No single company has a monopoly on innovation, so pharmaceutical manufacturers need to continually find ways to complement their strong internal research with creative external alliances. Analysts expect that more than 50 per cent of new drug approvals in 2004 will originate from the biotech sector, highlighting the importance of accessing this source of innovation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Nigel Sheail, Global Head, Strategic Alliances & Acquisitions at Roche Pharma Partnering

Nigel Sheail is Global Head of Strategic Alliances & Acquisitions at Roche Pharma Partnering. He started at Roche as a local Finance Director, setting up the company's operations in China, and later worked as the Global Controller for Research. Nigel, originally trained as a Molecular Biologist and a qualified Chartered Accountant, held several positions at GlaxoSmithKline before joining Roche more than 10 years ago. Nigel's Strategic Alliances & Acquisitions team is responsible for identifying and accessing strategic partnering opportunities. He has been responsible for a broad range of deals from research and technology collaborations through to Phase III product licensing opportunities.

spacer
Nigel Sheail
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

X-Chem Acquires ComInnex

WALTHAM, Mass.; Oct. 25, 2021 (Business Wire) X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement